ArticleIn vitro cellular & developmental biology. Animal2026
Total flavonoids of Rhizoma Drynariae promote osteogenic differentiation of tendon-derived stem cells through the TGF-β/BMP signaling pathway, thereby improving bone regeneration after anterior cruciate ligament reconstruction in rats.
Article in In vitro cellular & developmental biology. Animal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor tendon-bone healing is a major challenge after anterior cruciate ligament reconstruction (ACLR). TFRD, the total flavonoids of Rhizoma Drynariae, has pharmacological effects in promoting bone formation, but it remains less understood whether it accelerates tendon-bone healing by regulating the osteogenic differentiation of tendon-derived stem cells (TDSCs). TDSCs were isolated from the Achilles tendons of rats and characterized for their stem cell properties through flow cytometry and multilineage differentiation assays. The effects of TFRD on TDSC proliferation, migration, and osteogenic differentiation were evaluated using the cell counting kit-8 assay, scratch wound healing assays, Alizarin Red S staining, and Western blot analysis. Gene and protein expression levels associated with the transforming growth factor-β/bone morphogenetic protein (TGF-β/BMP) signaling pathway were assessed by real-time quantitative polymerase chain reaction and Western blot. A rat ACLR model was created and divided into four experimental groups: Sham, ACLR, TFRD, and TFRD + Noggin. Tendon-bone healing was analyzed using hematoxylin and eosin staining, Masson's trichrome staining, bone mineral density measurements, and immunohistochemistry. Noggin was used to inhibit BMP signaling for pathway validation. TFRD (50-100 μg/mL) significantly enhanced the proliferation, migration, and osteogenic differentiation of TDSCs, and increased the expression of key osteogenic markers, including runt-related transcription factor 2 (RUNX2) and alkaline phosphatase (ALP). Mechanistically, TFRD activated the TGF-β/BMP signaling pathway, leading to elevated levels of TGF-β1, BMP-2, and phosphorylated Smad1/5/8. Moreover, TGF-β1 extended the duration of BMP-2 signaling and suppressed Noggin expression. The osteogenic effects of TFRD were diminished when Noggin was applied, indicating its role in modulating the BMP pathway. In vivo, TFRD significantly improved collagen fiber alignment, calcification, and bone mineral density at the tendon-bone junction, while also upregulating RUNX2 and ALP expression. TFRD promotes osteogenic differentiation of TDSCs by activating the TGF-β/BMP signaling pathway, improves tendon-bone healing after ACLR, and provides experimental support for its clinical application.
Indexed as
Identifiers
42484774What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.